This Nov 3rd, join us for the third edition of Business of Cannabis: New York at the New York Academy of Medicine. A day long leadership summit focused on retail, investment & policy across New York and North America. Tickets on-sale now – www.cannabisnewyork.live
Psychemedics has announced the launch of a new drug screening panel – Advanced 5-Panel Drug Screen – that has removed cannabis from the screening and prioritises screening for fentanyl.
Described as a leap forward in drug screening technology, the screening test is able to detect cocaine, opioids, PCP and amphetamines.
Psychmedics highlights that as the country grapples with an ongoing labour shortage and in light of the 49 states that have made the decision to legalise cannabis, there is a need for change in drug screening tests
It stated: “Traditional 5-panel drug tests, rooted in a four-decade-old paradigm, have failed to evolve in today’s drug market and are unable to detect the rising drug, fentanyl.”
President and CEO at Psychemedics, Brian Hullinger, commented: “Few challenges in the workplace have undergone as dramatic a transformation as the shifting dynamics between marijuana and fentanyl. Recognising this shift, Psychemedics has developed the Advanced 5-Panel to bridge the gap.”
According to Psychemedics, the panel is 25 times more effective at detecting opioids, 23 times more accurate in identifying cocaine use and 13 times more adept at pinpointing amphetamine use.
